Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea A.

Slides:

Advertisements

Similar presentations

THE DIABETES PREVENTION PROGRAM RESEARCH GROUP*

Advertisements

TROPHY TRial Of Preventing HYpertension. High-normal BP increases CV risk Vasan RS et al. N Engl J Med. 2001;345: Incidence of CV events in women.

Farxiga™ - Dapagliflozin

Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy: A Randomized Double-Blind Trial of Saxagliptin Plus Dapagliflozin.

Journal Club 埼玉医科大学総合医療センター内分泌・糖尿病内科 Department of Endocrinology and Diabetes, Saitama Medical Center, Saitama Medical University 松田昌文 Matsuda, Masafumi.

Glucagon-Like Peptide 1 Receptor Agonist or Bolus Insulin With Optimized Basal Insulin in Type 2 Diabetes Featured Article: Michaela Diamant, Michael A.

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia.

Liraglutide and the Preservation of Pancreatic β-Cell Function in Early Type 2 Diabetes: The LIBRA Trial Featured Article: Ravi Retnakaran, Caroline K.

Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1)

Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections.

Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes.

Rapid Rise in Hypertension and Nephropathy in Youth With Type 2 Diabetes The TODAY clinical trial Featured Article: TODAY Study Group* Diabetes Care Volume.

Long-Term Efficacy of Dapagliflozin in T2DM Patients Receiving High-Dose Insulin John P.H. Wilding, DM, FRCP 

An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia.

Downloaded from Slide 1 Dual Inhibition of Two Sources of Cholesterol: Absorption and Production in Patients with Type 2 Diabetes.

Mechanisms of Glucose Lowering of Dipeptidyl Peptidase-4 Inhibitor Sitagliptin When Used Alone or With Metformin in Type 2 Diabetes A double-tracer study.

Metabolic Effects of Bariatric Surgery

Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy Kahn SE, et al. (ADOPT Study Group) N Engl J Med 2006;355: Steven E. Kahn,

Maternal Efficacy and Safety Outcomes in a Randomized, Controlled Trial Comparing Insulin Detemir With NPH Insulin in 310 Pregnant Women With Type 1 Diabetes.

Improving Outcomes with SGLT2 Cotransporter Inhibitors in Challenging T2DM Patients Part 3 of 4.

Journal Club 亀田メディカルセンター糖尿病内分泌内科 Diabetes and Endocrine Department, Kameda Medical Center 松田昌文 Matsuda, Masafumi 2007 年 11 月 1 日 8:20-8:50 B 棟８階カンファレンス室.

A Diabetes Outcome Progression Trial

Part 10. FPG (mg/dL) BaselineDay 8Day 15 Vehicle (n=6) 0.01 mg/kg (n=6) 0.1 mg/kg (n=6) 1 mg/kg (n=6) 10 mg/kg (n=6) *P

Clinical Trial Results. org Anti-Inflammatory Effects of Pioglitazone and/or Simvastatin in High Cardiovascular Risk Patients With Elevated High Sensitivity.

Improving Outcomes with SGLT2 Cotransporter Inhibitors in Challenging T2DM Patients Part 1.

Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.

 SC Guidelines for Diabetes Care Screening for Diagnosis of Diabetes To test for diabetes or to assess risk of future diabetes, either A1C, Fasting.

Type 2 diabetes treatment: Old and New Emily Szmuilowicz, MD, MS Assistant Professor of Medicine Division of Endocrinology Northwestern University.

A Controlled Trial of Renal Denervation for Resistant Hypertension

Adding Prandial Insulin to Basal Insulin: Key Challenges

Safety and Efficacy of Sitagliptin Therapy for the Inpatient Management of General Medicine and Surgery Patients With Type 2 Diabetes A pilot, randomized,

Liraglutide Promotes Natriuresis but Does Not Increase Circulating Levels of Atrial Natriuretic Peptide in Hypertensive Subjects With Type 2 Diabetes Featured.

Diabetes Prevention Program (DPP)

Int J Clin Pract, December 2013, 67, 12,

Efficacy and Safety of Canaglifozin, a Sodium- Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes Featured Article:

Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension Featured Article: Ilkka Tikkanen, Kirsi Narko, Cordula Zeller, Alexandra.

Flow of Patients Through the Trial Nissen SE, et al. JAMA 2008;299:

GLP-1 Agonists and DPP-4 Inhibitors How do they work? Part 3.

Downloaded from Slide 1 Dual Inhibition of Two Sources of Cholesterol: Absorption and Production Results of a Clinical Trial.

Patients’ Assignments,Values at Screening, and Baseline Efficacy and Safety Values - PartI JP Després, N Engl J Med 2005; 353:

Featured Article: Wayne H.-H. Sheu, Ira Gantz, Menghui Chen, Shailaja Suryawanshi, Arpana Mirza, Barry J. Goldstein, Keith D. Kaufman, and Samuel S. Engel.

Slideset on: Gathe J, da Silva BA, Cohen DE, et al. A once-daily lopinavir/ritonavir-based regimen is noninferior to twice-daily dosing and results in.

Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine A 24-Week,

 Insulin Degludec  Ultra long action  Due to formation of soluble multihexamers at the injection site from which monomers gradually separate and are.

The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose- Ranging.

R1. 이정미 / prof. 이상열. INTRODUCTION Type 2 diabetes is a major risk factor for cardiovascular disease The presence of both type 2 diabetes and.

Impact of Age and Estimated Glomerular Filtration Rate on the Glycemic Efficacy and Safety of Canagliflozin: A Pooled Analysis of Clinical Studies Richard.

Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive.

From ESH 2016 | POS 7D: Jan Rosa, MD

Copyright © 2002 American Medical Association. All rights reserved.

Neal B, et al. Diabetes Care 2015;38:403–411

Dapagliflozin Improves Hyperglycemia and Beta-Cell Function Without Increasing Hypoglycemic Episodes in Patients With Type 2 Diabetes Mellitus Afshin Salsali.

Canagliflozin: Real World Experience

Empagliflozin (Jardiance®)

MK-0431 P051 PDT APPROVED 4/10/09 11/13/2018 2:49 PM

Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: How Do They Exert Their Metabolic Actions? Part 3.

Diabetes Journal Club Julie Shah.

Sodium-glucose co-transporter 2 (SGLT2) inhibitors work by blocking the reabsorption of filtered glucose in the kidneys. This leads to glucosuria and improved.

Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients Evan Stein, MD, Harold Bays, MD, Michael Koren,

Summary of DURATION development program select efficacy results: absolute difference in change in A1C, body weight, systolic blood pressure, and LDL cholesterol.

SUSTAIN-6 Trial design: Patients with DM2 at high risk for CV events were randomized in a 1:1:1:1 fashion to either semaglutide 0.5 mg, semaglutide 1 mg,

Changes in A1C (A), body weight (B), and systolic blood pressure (C) with canagliflozin in combination with incretin-based therapies. *In the dose-advancement.

(p for noninferiority < 0.001)

Side-by-side comparison of change in A1C with canagliflozin versus DPP-4 inhibitors in randomized clinical trials and the real-world study. *Data are LS.

Flow of Patients Through the Trial

Flow of Patients Through Trial

Baseline Characteristics, Blood Pressures, and Laboratory Values

Effect of empagliflozin on efficacy parameters at week 18.

Glycemic control and body weight over 52 weeks.

Glycemic control in Hispanic and non-Hispanic patients during the SWITCH 2 trial. Glycemic control in Hispanic and non-Hispanic patients during the SWITCH.

Presentation transcript:

Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea A 52-week randomized trial Featured Article: Guntram Schernthaner, M.D., Jorge L. Gross, M.D., Julio Rosenstock, M.D., Michael Guarisco, M.D., Min Fu, M.S., Jacqueline Yee, M.S., Masato Kawaguchi, M.D., William Canovatchel, M.D., Gary Meininger, M.D. Diabetes Care Volume 36: September, 2013

STUDY OBJECTIVE To evaluate the efficacy and safety of canagliflozin compared with sitagliptin in subjects with type 2 diabetes inadequately controlled with metformin plus sulfonylurea Schernthaner G. et al. Diabetes Care 2013;36:

STUDY DESIGN AND METHODS Subjects using stable metformin plus sulfonylurea received 300 mg canagliflozin or 100 mg sitagliptin daily Primary end point was change from baseline in A1C at 52 weeks Secondary end points included change in fasting plasma glucose (FPG) and systolic blood pressure (BP) and percent change in body weight, triglycerides, and HDL cholesterol Safety was assessed base on adverse event (AE) reports Schernthaner G. et al. Diabetes Care 2013;36:

RESULTS At 52 weeks, 300 mg canagliflozin demonstrated noninferiority and, in a subsequent assessment, showed superiority to 100 mg sitagliptin in reducing A1C Greater reductions in FPG, body weight, and systolic BP were observed with canagliflozin versus sitagliptin Overall AE rates were similar with canagliflozin and sitagliptin Schernthaner G. et al. Diabetes Care 2013;36:

RESULTS Incidence of serious AEs and AE-related discontinuations was low for both groups Higher incidences of genital mycotic infections and osmotic diuresis–related AEs were observed with canagliflozin Hypoglycemia rates were similar in both groups Schernthaner G. et al. Diabetes Care 2013;36:

CONCLUSIONS Canagliflozin may provide better improvement in glycemic control and body weight reduction than sitagliptin Increased genital infections may occur in subjects with type 2 diabetes using metformin plus sulfonylurea Schernthaner G. et al. Diabetes Care 2013;36: